Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00758264 |
The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 and pneumococcal vaccine GSK1024850A when co-administered, compared to each vaccine administered individually.
Condition | Intervention | Phase |
---|---|---|
Meningococcal Disease Pneumococcal Disease. |
Biological: Meningococcal vaccine GSK134612 Biological: Pneumococcal vaccine GSK1024850A |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-administered With GSK Biologicals' Pneumococcal Vaccine GSK1024850A in Healthy 12-23-month-old Children Previously Primed With GSK1024850A |
Enrollment: | 363 |
Study Start Date: | October 2008 |
Study Completion Date: | June 2009 |
Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Group B: Active Comparator
Pneumococcal vaccine GSK1024850A followed one month later by meningococcal vaccine GSK134612.
|
Biological: Meningococcal vaccine GSK134612
Single dose intramuscular injection.
Biological: Pneumococcal vaccine GSK1024850A
Single dose intramuscular injection.
|
Group A: Experimental
Meningococcal vaccine GSK134612 co-administered with pneumococcal vaccine GSK1024850A.
|
Biological: Meningococcal vaccine GSK134612
Single dose intramuscular injection.
Biological: Pneumococcal vaccine GSK1024850A
Single dose intramuscular injection.
|
Group C: Active Comparator
Meningococcal vaccine GSK134612 followed one month later by pneumococcal vaccine GSK1024850A.
|
Biological: Meningococcal vaccine GSK134612
Single dose intramuscular injection.
Biological: Pneumococcal vaccine GSK1024850A
Single dose intramuscular injection.
|
Multi-center study with 3 parallel groups. One group will receive 2 vaccines injections at the same visit (pneumococcal+ meningococcal), one group will receive a pneumococcal vaccine followed one month later by a meningococcal vaccine, and the last group will receive the meningococcal vaccine followed one month later by the pneumococcal vaccine. All subjects will have one blood sample taken before vaccination and one blood sample taken one month after each vaccination (i.e. the first group will have 2 blood samples taken, and the other two groups will have 3 blood sample taken)
Ages Eligible for Study: | 12 Months to 23 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Mexico | |
GSK Investigational Site | |
Mexico city, Mexico, 14000 | |
GSK Investigational Site | |
Mexico, Mexico, 14080 | |
Taiwan | |
GSK Investigational Site | |
Taoyuan Hsien, Taiwan | |
GSK Investigational Site | |
Taipei, Taiwan, 105 | |
GSK Investigational Site | |
Taipei, Taiwan, 100 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 111393 |
Study First Received: | September 23, 2008 |
Last Updated: | September 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00758264 History of Changes |
Health Authority: | Mexico: Ministry of Health; Taiwan: Department of Health |
Meningococcal vaccine Pneumococcal vaccine Routine infancy vaccination Immunogenicity Safety |
Bacterial Infections Meningococcal Infections Healthy |
Meningococcal Infection Gram-Negative Bacterial Infections Neisseriaceae Infections |
Bacterial Infections Meningococcal Infections Gram-Negative Bacterial Infections Neisseriaceae Infections |